This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Touho, H. Articles by Ohnishi, H. Search for Related Content PubMed PubMed Citation Articles by Touho, H. Articles by Ohnishi, H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETAZOLAMIDE Medline Plus Health Information Nuclear Scans

(Stroke. 1996;27:282-289.)
© 1996 American Heart Association, Inc.

Articles

Preoperative and Postoperative Evaluation of Cerebral Perfusion and Vasodilatory Capacity With ^99mTc-HMPAO SPECT and Acetazolamide in Childhood Moyamoya Disease

Hajime Touho, MD; Jun Karasawa, MD Hideyuki Ohnishi, MD

From the Department of Neurosurgery, Osaka Neurological Institute (Japan).

Correspondence to Hajime Touho, MD, Department of Neurosurgery, Osaka Neurological Institute, 2-6-23 Shonai Takara-machi, Toyonaka, Osaka 561, Japan.

Background and Purpose The results of long-term follow-up studies of cerebral perfusion and vasodilatory capacity following administration of acetazolamide after serial vascular reconstructions in 25 patients with childhood moyamoya disease are reported.

Methods Cerebral perfusion was measured with ^99mTc-hexamethylpropyleneamine oxime single-photon emission CT before and after IV administration of 10 mg/kg acetazolamide, which was performed both before and after vascular reconstruction by superficial temporal artery-middle cerebral artery anastomosis and encephalomyosynangiosis (first and second operations) and/or omental transplantation to the brain (third operation).

Results Follow-up periods ranged between 12 and 24 months (mean±SD, 18.5±3.2 months) after the first operation. Repetitive transient ischemic attacks disappeared completely after serial vascular reconstructions in all patients. Before the first operation, cerebral perfusion in the territory of the middle cerebral artery on the side of initial operation was 83.9±4.7% and was significantly lower than that in the contralateral side (88.3±4.9%, n=25; P<.0001, paired t test). Vasodilatory capacity on the side of the first operation was -18.4±2.5% and that on the contralateral side -14.4±2.1%. The former value was significantly lower than the latter value (n=25; P<.0001, paired t test). After the first operation, cerebral perfusion and vasodilatory capacity on the side of initial operation were markedly improved, to 87.8±4.5% and -14.7±2.7%, respectively (n=25; P<.0001, both cases, paired t test). Before the second operation, cerebral perfusion and vasodilatory capacity on the side of the second operation were 76.6±4.1% and -20.1±1.9%, respectively, and significantly lower than those before the first operation (n=25; P<.0001, both cases, paired t test). Eight patients subsequently required bifrontal omental transplantation for repetitive paraparetic transient ischemic attacks after the second operation; they had low cerebral perfusion and vasodilatory capacity bilaterally in the territories of the anterior cerebral arteries (72.4±2.7% and -18.6±1.7%, respectively). After omental transplantation, both were significantly increased, to 81.9±3.4% and -11.8±1.9%, respectively (n=25; P<.0001, both cases, paired t test).

Conclusions Hemodynamic compromise existed in patients with childhood moyamoya disease and was a major cause of development of ischemic symptoms. Regions in which hemodynamic compromise was present could be determined by measuring regional cerebral perfusion and vasodilatory capacity.

Key Words: acetazolamide • child • moyamoya disease • perfusion • vasodilation

This article has been cited by other articles:

				Y. So, H.-Y. Lee, S.-K. Kim, J. S. Lee, K.-C. Wang, B.-K. Cho, E. Kang, and D. S. Lee Prediction of the Clinical Outcome of Pediatric Moyamoya Disease With Postoperative Basal/Acetazolamide Stress Brain Perfusion SPECT After Revascularization Surgery Stroke, July 1, 2005; 36(7): 1485 - 1489. [Abstract] [Full Text] [PDF]

				T Nariai, Y Matsushima, S Imae, Y Tanaka, K Ishii, M Senda, and K Ohno Severe haemodynamic stress in selected subtypes of patients with moyamoya disease: a positron emission tomography study J. Neurol. Neurosurg. Psychiatry, May 1, 2005; 76(5): 663 - 666. [Abstract] [Full Text] [PDF]

				H.-Y. Lee, J. C. Paeng, D. S. Lee, J. S. Lee, C. W. Oh, M. J. Cho, J.-K. Chung, and M. C. Lee Efficacy Assessment of Cerebral Arterial Bypass Surgery Using Statistical Parametric Mapping and Probabilistic Brain Atlas on Basal/Acetazolamide Brain Perfusion SPECT J. Nucl. Med., February 1, 2004; 45(2): 202 - 206. [Abstract] [Full Text] [PDF]

				K. Ogasawara, T. Okuguchi, M. Sasoh, M. Kobayashi, H. Yukawa, K. Terasaki, T. Inoue, and A. Ogawa Qualitative versus Quantitative Assessment of Cerebrovascular Reactivity to Acetazolamide Using iodine-123-N-Isopropyl-p-Iodoamphetamine SPECT in Patients with Unilateral Major Cerebral Artery Occlusive Disease AJNR Am. J. Neuroradiol., June 1, 2003; 24(6): 1090 - 1095. [Abstract] [Full Text] [PDF]

				S.-K. Lee, D. I. Kim, E.-K. Jeong, S.-Y. Kim, S. H. Kim, Y. K. In, D.-S. Kim, and J.-U. Choi Postoperative Evaluation of Moyamoya Disease with Perfusion-Weighted MR Imaging: Initial Experience AJNR Am. J. Neuroradiol., April 1, 2003; 24(4): 741 - 747. [Abstract] [Full Text] [PDF]

				M. Bonduel, M. Hepner, G. Sciuccati, A. F. Torres, S. Tenembaum, and G. de Veber Prothrombotic Disorders in Children With Moyamoya Syndrome Editorial Comment Stroke, August 1, 2001; 32(8): 1786 - 1792. [Abstract] [Full Text] [PDF]